TY - JOUR
T1 - Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication
AU - Hung, Kuei Hsiang
AU - Yang, Hsiao Bai
AU - Cheng, Hsiu Chi
AU - Wu, Jiunn Jong
AU - Sheu, Bor Shyang
PY - 2010/1
Y1 - 2010/1
N2 - Background and Aim: The intestinal metaplasia (IM) has overexpressions of cyclooxygenase-2 (COX-2) and β-catenin. This pilot study assessed whether celecoxib, a selective COX-2 inhibitor, could regress IM that persisted long term after Helicobacter pylori eradication. Methods: Thirty-three patients with H. pylori eradication were enrolled in the present study due to the persistence of IM after a 3-year follow up. These patients received celecoxib 200 mg/day for 8 weeks, and were serially checked for levels of blood urea nitrogen and creatinine once per 2 weeks. After 8-week celecoxib treatment, IM regression was assessed by panendoscopy. The gastric specimens, taken before and after celecoxib, were immunochemically stained for COX-2 and β-catenin. Results: The intention-to-treat and per-protocol analyses to the rates of IM regression by 8-week celecoxib treatment were 24.2% (8/33) and 28.6% (8/28), respectively. All enrolled patients had no renal impairment. Even in the patients without total IM regression, mean IM scores in the antrum decreased after 8-week celecoxib treatment (P = 0.007). The patients with complete regression of IM after 8-week celecoxib treatment had a significantly lower COX-2 expression, but not β-catenin expression, at enrollment than those patients without IM regression (P = 0.031). Conclusion: Short-term celecoxib treatment can be safe and promising to regress long-term persistent IM after H. pylori eradication.
AB - Background and Aim: The intestinal metaplasia (IM) has overexpressions of cyclooxygenase-2 (COX-2) and β-catenin. This pilot study assessed whether celecoxib, a selective COX-2 inhibitor, could regress IM that persisted long term after Helicobacter pylori eradication. Methods: Thirty-three patients with H. pylori eradication were enrolled in the present study due to the persistence of IM after a 3-year follow up. These patients received celecoxib 200 mg/day for 8 weeks, and were serially checked for levels of blood urea nitrogen and creatinine once per 2 weeks. After 8-week celecoxib treatment, IM regression was assessed by panendoscopy. The gastric specimens, taken before and after celecoxib, were immunochemically stained for COX-2 and β-catenin. Results: The intention-to-treat and per-protocol analyses to the rates of IM regression by 8-week celecoxib treatment were 24.2% (8/33) and 28.6% (8/28), respectively. All enrolled patients had no renal impairment. Even in the patients without total IM regression, mean IM scores in the antrum decreased after 8-week celecoxib treatment (P = 0.007). The patients with complete regression of IM after 8-week celecoxib treatment had a significantly lower COX-2 expression, but not β-catenin expression, at enrollment than those patients without IM regression (P = 0.031). Conclusion: Short-term celecoxib treatment can be safe and promising to regress long-term persistent IM after H. pylori eradication.
UR - http://www.scopus.com/inward/record.url?scp=73449098952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73449098952&partnerID=8YFLogxK
U2 - 10.1111/j.1440-1746.2009.05974.x
DO - 10.1111/j.1440-1746.2009.05974.x
M3 - Article
C2 - 19793174
AN - SCOPUS:73449098952
SN - 0815-9319
VL - 25
SP - 48
EP - 53
JO - Journal of Gastroenterology and Hepatology (Australia)
JF - Journal of Gastroenterology and Hepatology (Australia)
IS - 1
ER -